Finding 570074 (2024-026)

Significant Deficiency
Requirement
G
Questioned Costs
$1
Year
2024
Accepted
2025-07-02
Audit: 361368
Auditor: Dwc

AI Summary

  • Core Issue: Solvista Health claimed software costs that exceeded the limits set in the grant agreement.
  • Impacted Requirements: Costs must be allowable under 2 CFR 200.403(a) and adhere to earmarking restrictions in the grant.
  • Recommended Follow-Up: Implement internal controls to monitor compliance with budget categories and verify costs before submitting reimbursement requests.

Finding Text

Criteria or Specific Requirement: In accordance with 2 CFR 200.403(a), costs charged to a federal award must be allowable under the provisions of the cost principles, the terms and conditions of the award, and the approved budget. Additionally, earmarking requirements in the grant agreement and associated budget restrict specific categories of expenditures, including a cap on allowable software costs. Condition: During our testing of expenditures claimed for reimbursement, we noted that Solvista Health incurred and claimed software-related costs in excess of the grant agreement, which explicitly limits allowable software expenditures. Context: The software expenditures submitted exceeded the software costs allowed per the grant agreement. Questioned Costs: $2,814 consisting of exceeded software expenditures submitted for reimbursement. Cause: Solvista Health did not have adequately designed and implemented internal controls related to monitoring of compliance with earmarking requirements specific to software expenditures under the terms of the grant. Effect: Solvista Health exceeded the allowable software cost limit established by the grant. Identification as a Repeat Finding: Not a repeat finding. Recommendation: We recommend that Solvista Health design and implement grant monitoring internal controls to ensure expenditures comply with all earmarking limitations specified in grant agreements and approved budgets. In particular, Solvista Health should implement procedures to track expenditures by budget category and verify compliance prior to submitting reimbursement requests.

Corrective Action Plan

agreement, the Group will implement grant monitoring internal controls and procedures to ensure that expenditures comply with all earmarking limitations specified in grant agreements and approved budgets. These procedures will track expenditures by budget category and verify compliance prior to submitting reimbursement requests.

Categories

Questioned Costs Allowable Costs / Cost Principles Matching / Level of Effort / Earmarking Subrecipient Monitoring Cash Management

Other Findings in this Audit

  • 570052 2024-015
    Material Weakness
  • 570053 2024-016
    Material Weakness
  • 570054 2024-018
    Significant Deficiency
  • 570055 2024-019
    Significant Deficiency
  • 570056 2024-019
    Significant Deficiency
  • 570057 2024-019
    Significant Deficiency
  • 570058 2024-020
    Significant Deficiency
  • 570059 2024-020
    Significant Deficiency
  • 570060 2024-020
    Significant Deficiency
  • 570061 2024-021
    Significant Deficiency
  • 570062 2024-022
    Significant Deficiency
  • 570063 2024-022
    Significant Deficiency
  • 570064 2024-022
    Significant Deficiency
  • 570065 2024-022
    Significant Deficiency
  • 570066 2024-023
    Significant Deficiency
  • 570067 2024-023
    Significant Deficiency
  • 570068 2024-023
    Significant Deficiency
  • 570069 2024-023
    Significant Deficiency
  • 570070 2024-024
    Significant Deficiency
  • 570071 2024-024
    Significant Deficiency
  • 570072 2024-025
    Significant Deficiency
  • 570073 2024-025
    Significant Deficiency
  • 570075 2024-027
    Significant Deficiency
  • 570076 2024-027
    Significant Deficiency
  • 570077 2024-028
    Significant Deficiency
  • 570078 2024-029
    Significant Deficiency
  • 570079 2024-029
    Significant Deficiency
  • 570080 2024-029
    Significant Deficiency
  • 570081 2024-014
    Material Weakness
  • 570082 2024-014
    Material Weakness
  • 570083 2024-014
    Material Weakness
  • 570084 2024-014
    Material Weakness
  • 570085 2024-014
    Material Weakness
  • 570086 2024-014
    Material Weakness
  • 570087 2024-014
    Material Weakness
  • 570088 2024-014
    Material Weakness
  • 570089 2024-014
    Material Weakness
  • 570090 2024-014
    Material Weakness
  • 570091 2024-014
    Material Weakness
  • 570092 2024-014
    Material Weakness
  • 570093 2024-017
    Significant Deficiency
  • 570094 2024-017
    Significant Deficiency
  • 570095 2024-029
    Significant Deficiency
  • 1146494 2024-015
    Material Weakness
  • 1146495 2024-016
    Material Weakness
  • 1146496 2024-018
    Significant Deficiency
  • 1146497 2024-019
    Significant Deficiency
  • 1146498 2024-019
    Significant Deficiency
  • 1146499 2024-019
    Significant Deficiency
  • 1146500 2024-020
    Significant Deficiency
  • 1146501 2024-020
    Significant Deficiency
  • 1146502 2024-020
    Significant Deficiency
  • 1146503 2024-021
    Significant Deficiency
  • 1146504 2024-022
    Significant Deficiency
  • 1146505 2024-022
    Significant Deficiency
  • 1146506 2024-022
    Significant Deficiency
  • 1146507 2024-022
    Significant Deficiency
  • 1146508 2024-023
    Significant Deficiency
  • 1146509 2024-023
    Significant Deficiency
  • 1146510 2024-023
    Significant Deficiency
  • 1146511 2024-023
    Significant Deficiency
  • 1146512 2024-024
    Significant Deficiency
  • 1146513 2024-024
    Significant Deficiency
  • 1146514 2024-025
    Significant Deficiency
  • 1146515 2024-025
    Significant Deficiency
  • 1146516 2024-026
    Significant Deficiency
  • 1146517 2024-027
    Significant Deficiency
  • 1146518 2024-027
    Significant Deficiency
  • 1146519 2024-028
    Significant Deficiency
  • 1146520 2024-029
    Significant Deficiency
  • 1146521 2024-029
    Significant Deficiency
  • 1146522 2024-029
    Significant Deficiency
  • 1146523 2024-014
    Material Weakness
  • 1146524 2024-014
    Material Weakness
  • 1146525 2024-014
    Material Weakness
  • 1146526 2024-014
    Material Weakness
  • 1146527 2024-014
    Material Weakness
  • 1146528 2024-014
    Material Weakness
  • 1146529 2024-014
    Material Weakness
  • 1146530 2024-014
    Material Weakness
  • 1146531 2024-014
    Material Weakness
  • 1146532 2024-014
    Material Weakness
  • 1146533 2024-014
    Material Weakness
  • 1146534 2024-014
    Material Weakness
  • 1146535 2024-017
    Significant Deficiency
  • 1146536 2024-017
    Significant Deficiency
  • 1146537 2024-029
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.696 Certified Community Behavioral Health Clinic Expansion Grants $381,902
93.778 Medical Assistance Program $349,300
93.575 Child Care and Development Block Grant $334,148
21.027 Coronavirus State and Local Fiscal Recovery Funds $219,142
93.665 Emergency Grants to Address Mental and Substance Use Disorders During Covid-19 $124,108
16.745 Criminal and Juvenile Justice and Mental Health Collaboration Program $114,870
93.870 Maternal, Infant and Early Childhood Home Visiting Grant $75,205
93.958 Block Grants for Community Mental Health Services $20,000
93.069 Public Health Emergency Preparedness $10,300